-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Viridian Therapeutics (NASDAQ:VRDN) Vs. DermTech (NASDAQ:DMTK) Critical Contrast
Viridian Therapeutics (NASDAQ:VRDN) Vs. DermTech (NASDAQ:DMTK) Critical Contrast
Viridian Therapeutics (NASDAQ:VRDN – Get Rating) and DermTech (NASDAQ:DMTK – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
Insider and Institutional Ownership
75.1% of DermTech shares are owned by institutional investors. 4.5% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 3.6% of DermTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Get Viridian Therapeutics alerts:Analyst Ratings
This is a summary of current ratings for Viridian Therapeutics and DermTech, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Viridian Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
DermTech | 0 | 1 | 3 | 0 | 2.75 |
Profitability
This table compares Viridian Therapeutics and DermTech's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Viridian Therapeutics | -10,981.32% | -206.72% | -50.48% |
DermTech | -748.29% | -49.02% | -43.48% |
Valuation and Earnings
This table compares Viridian Therapeutics and DermTech's top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Viridian Therapeutics | $2.96 million | 234.54 | -$79.41 million | ($4.61) | -5.29 |
DermTech | $11.84 million | 13.85 | -$78.33 million | ($3.56) | -1.53 |
DermTech has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Viridian Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, DermTech has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Summary
DermTech beats Viridian Therapeutics on 10 of the 14 factors compared between the two stocks.
About Viridian Therapeutics
(Get Rating)
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
About DermTech
(Get Rating)
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Viridian Therapeutics (NASDAQ:VRDN – Get Rating) and DermTech (NASDAQ:DMTK – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
納斯達克:VRDN-GET評級)和德美科技(納斯達克:DMTK-GET評級)都是小盤醫療公司,但哪一家是優勢業務?我們將根據這兩家公司的收益、估值、分析師建議、盈利能力、股息、機構所有權和風險等方面的實力進行比較。
Insider and Institutional Ownership
內部人與機構持股
75.1% of DermTech shares are owned by institutional investors. 4.5% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 3.6% of DermTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
75.1%的DermTech股份由機構投資者持有。Viridian Treateutics 4.5%的股份由公司內部人士持有。相比之下,DermTech 3.6%的股份由公司內部人士持有。強大的機構持股表明,捐贈基金、對衝基金和大型基金管理公司相信,一家公司有望實現長期增長。
Analyst Ratings
分析師評級
This is a summary of current ratings for Viridian Therapeutics and DermTech, as reported by MarketBeat.com.
這是MarketBeat.com報道的Viridian Treeutics和DermTech的當前評級摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Viridian Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
DermTech | 0 | 1 | 3 | 0 | 2.75 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
病毒學治療學 | 0 | 0 | 6 | 0 | 3.00 |
皮姆泰克 | 0 | 1 | 3 | 0 | 2.75 |
Profitability
盈利能力
This table compares Viridian Therapeutics and DermTech's net margins, return on equity and return on assets.
此表比較了Viridian Treeutics和DermTech的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Viridian Therapeutics | -10,981.32% | -206.72% | -50.48% |
DermTech | -748.29% | -49.02% | -43.48% |
淨利潤率 | 股本回報率 | 資產回報率 | |
病毒學治療學 | -10,981.32% | -206.72% | -50.48% |
皮姆泰克 | -748.29% | -49.02% | -43.48% |
Valuation and Earnings
估值和收益
This table compares Viridian Therapeutics and DermTech's top-line revenue, earnings per share (EPS) and valuation.
此表比較了Viridian Treeutics和DermTech的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Viridian Therapeutics | $2.96 million | 234.54 | -$79.41 million | ($4.61) | -5.29 |
DermTech | $11.84 million | 13.85 | -$78.33 million | ($3.56) | -1.53 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
病毒學治療學 | 296萬美元 | 234.54 | -7,941萬美元 | ($4.61) | -5.29 |
皮姆泰克 | 1184萬美元 | 13.85 | -7,833萬元 | ($3.56) | -1.53 |
DermTech has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
DermTech的收入和收益比Viridian Treeutics高。Viridian Treeutics的市盈率低於DermTech,這表明它目前是兩隻股票中更負擔得起的一隻。
Risk and Volatility
風險和波動性
Viridian Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, DermTech has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Viridian Treateutics的貝塔係數為1.13,這意味着其股價的波動性比標準普爾500指數高13%。相比之下,DermTech的貝塔係數為1.39,這意味着其股價的波動性比標準普爾500指數高39%。
Summary
摘要
DermTech beats Viridian Therapeutics on 10 of the 14 factors compared between the two stocks.
在兩隻股票之間的14個因素中,DermTech在10個因素上擊敗了Viridian Treeutics。
About Viridian Therapeutics
關於維裏迪安治療學
(Get Rating)
(獲取評級)
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Viridian治療公司是一家生物技術公司,為患有嚴重疾病的患者開發治療方法。它開發了人源化的抗IGF-1R抗體VRDN-001,用於治療甲狀腺眼病(TED)的1/2期臨牀試驗;VRDN-002,用於治療甲狀腺眼病的IGF-1R抗體;以及VRDN-003,用於治療TED的IGF-1R治療性抗體。該公司前身為miRagen治療公司,並於2021年1月更名為Viridian治療公司。Viridian治療公司成立於2006年,總部設在馬薩諸塞州沃爾瑟姆。
About DermTech
關於德美科技
(Get Rating)
(獲取評級)
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
分子診斷公司DermTech,Inc.開發和銷售新的非侵入性基因組測試,以診斷美國的皮膚癌、炎症性疾病和衰老相關疾病。它提供DermTech黑色素瘤測試(DMT),這是一種基因表達測試,可增強對基因組非典型性的早期檢測,並有助於排除黑色素瘤和對非典型色素病變進行手術活檢的必要性。該公司還提供粘性皮膚樣本採集試劑盒,以及Th1、Th2、幹擾素-伽馬和Th17炎症途徑的基因表達分析。此外,它正在開發紫外線損傷DNA風險評估產品,以及非黑色素瘤皮膚癌診斷和皮膚T細胞淋巴瘤排除測試產品,以及通過電子信息和電信技術提供與健康相關的信息服務。該公司主要向病理學和腫瘤學從業者銷售其產品。DemTech,Inc.總部設在加利福尼亞州的拉荷亞。
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Viridian Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Viridian Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧